Kymera Therapeutics, Inc. financial data

Symbol
KYMR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 North Beacon Street, 4 Th Floor, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 656 % +18.5%
Debt-to-equity 33.1 % +19.5%
Return On Equity -31.9 % +6.53%
Return On Assets -24 % +10.3%
Operating Margin -224 % +38.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.4 M shares +10.9%
Common Stock, Shares, Outstanding 61.4 M shares +11%
Entity Public Float 1.01 B USD +27.9%
Common Stock, Value, Issued 6 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 70.8 M shares +21.6%
Weighted Average Number of Shares Outstanding, Diluted 70.8 M shares +21.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 79.4 M USD +70.2%
Research and Development Expense 196 M USD +14.7%
General and Administrative Expense 56.9 M USD +24.2%
Operating Income (Loss) -178 M USD -4.94%
Income Tax Expense (Benefit) 200 K USD
Net Income (Loss) Attributable to Parent -155 M USD +2.81%
Earnings Per Share, Basic -2.51 USD/shares +12.2%
Earnings Per Share, Diluted -2.51 USD/shares +12.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.5 M USD +86.5%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 537 M USD +30.5%
Property, Plant and Equipment, Net 49.3 M USD +183%
Operating Lease, Right-of-Use Asset 49.3 M USD -12.9%
Other Assets, Noncurrent 2.12 M USD -32.9%
Assets 868 M USD +41.4%
Accounts Payable, Current 6.81 M USD +5.08%
Accrued Liabilities, Current 16 M USD -13.5%
Contract with Customer, Liability, Current 22.6 M USD -29.9%
Liabilities, Current 56.1 M USD -9.36%
Contract with Customer, Liability, Noncurrent 23.8 M USD -4.36%
Operating Lease, Liability, Noncurrent 76 M USD +18.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 157 M USD +3.39%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.78 M USD +41.5%
Retained Earnings (Accumulated Deficit) -579 M USD -36.4%
Stockholders' Equity Attributable to Parent 711 M USD +53.9%
Liabilities and Equity 868 M USD +41.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.6 M USD +9.96%
Net Cash Provided by (Used in) Financing Activities 354 M USD +30423%
Net Cash Provided by (Used in) Investing Activities -331 M USD -1445%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 61.4 M shares +11%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.4 M USD +9.78%
Interest Paid, Excluding Capitalized Interest, Operating Activities 49 K USD -5.77%
Deferred Tax Assets, Valuation Allowance 162 M USD +35.2%
Deferred Tax Assets, Gross 184 M USD +46.3%
Operating Lease, Liability 84.7 M USD +27.6%
Depreciation 4.2 M USD +31.3%
Payments to Acquire Property, Plant, and Equipment 7.4 M USD +84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -153 M USD +3.49%
Lessee, Operating Lease, Liability, to be Paid 131 M USD +10.7%
Property, Plant and Equipment, Gross 59.9 M USD +137%
Operating Lease, Liability, Current 8.76 M USD +243%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.4 M USD +2.42%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.1 M USD +5.16%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 46.5 M USD -10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.8 M USD +2.42%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.2 M USD +2.42%
Depreciation, Depletion and Amortization 1.46 M USD +66.2%
Deferred Tax Assets, Net of Valuation Allowance 21.7 M USD +278%
Share-based Payment Arrangement, Expense 45.7 M USD +23.5%